The analysis compared outcomes from the Phase III OASIS-4 trial and ATTAIN-1 in adults with overweight or obesity without diabetes.
Key opinion leaders interviewed by GlobalData recognised oral semaglutide as a meaningful addition to the obesity armamentarium. Credit: Uwe Aranas via Shutterstock.com.
On 15 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from a post-hoc indirect treatment comparison of Wegovy (oral semaglutide 25mg) versus Foundayo (orforglipron 36mg capsule; orforglipron 17.2mg tablet equivalent), both oral glucagon-like peptide-1 receptor agonists (GLP-1RA) recently approved in the US for chronic weight management, in adults with overweight or obesity, were presented. In the absence of a head-to-head clinical trial, this analysis aimed to evaluate the relative weight loss efficacy and tolerability of these two orally administered glucagon-like peptide-1 receptor agonists (GLP-1RAs) using data from their respective Phase III registration trials.
The analysis compared outcomes from the Phase III OASIS-4 trial (oral semaglutide; NCT05564117) and ATTAIN-1 (orforglipron; NCT05869903) in adults with overweight or obesity without diabetes. To address cross-trial differences, including body weight, sex distribution and glycaemic status, a simulated treatment comparison (STC) was used for treatment regimen and efficacy, while a two-stage matching-adjusted indirect comparison (2SMAIC) was applied to tolerability outcomes, aligning individual patient data from OASIS 4 to the ATTAIN-1 population.
